U.S. Markets closed

CohBar, Inc. (CWBR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.1300-0.0100 (-0.88%)
At close: 4:00PM EDT

1.1300 0.00 (0.00%)
After hours: 4:00PM EDT

CohBar, Inc.

1455 Adams Drive
Suite 2050
Menlo Park, CA 94025
United States
650 446 7888

Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Mr. Steven B. Engle M.S.CEO & Director424.73kN/A1955
Dr. Pinchas CohenCo-Founder & Independent Director64.12kN/A1957
Dr. Nir Yacov BarzilaiCo-Founder & Independent Director64.12kN/A1956
Mr. Jeffrey F. Biunno CPA, M.B.A., CPA, MBACFO, Treasurer & Sec.317.68k35.05k1966
Dr. Kenneth C. CundyChief Scientific Officer383.27k26.03k1959
Dr. David Andrew Sinclair A.O., Ph.D.Co-Founder, Advisor & ConsultantN/AN/A1970
Ms. Jordyn TaraziDirector of Investor RelationsN/AN/AN/A
Dr. Changhan David Lee Ph.D.Consultant of Mitochondrial BiologyN/AN/AN/A
Dr. Rohit LoombaScientific ConsultantN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Corporate Governance

CohBar, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 9. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 5; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.